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Introduction {#s1}
============

Age-related macular degeneration (AMD) is the most common cause of blindness in individuals over 50 years of age [@pone.0109744-Owen1]--[@pone.0109744-Kawasaki1]. Although an estimated 80% of patients with AMD have the non-neovascular (dry) form, the neovascular (wet) form is responsible for almost 90% of severe visual losses resulting from AMD [@pone.0109744-Schmier1]--[@pone.0109744-Ferris1]. Vascular endothelial growth factor-A (VEGF-A) has been proven to play a major role in the pathogenesis of wet AMD [@pone.0109744-Frampton1], [@pone.0109744-Ambati1]. Since the mid-2000s, antivascular endothelial growth factor (anti-VEGF) therapy has become the mainstay of treatment for wet AMD [@pone.0109744-Lally1].

Ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA, USA) is a recombinant humanized immunoglobulin G1κ isotype monoclonal antibody fragment directed toward all isoforms of VEGF-A [@pone.0109744-Frampton1]. It has been approved for the treatment of wet AMD by the food and drug administration (FDA) in the US (2006), Europe (2007), Japan (2009), and many other countries. However, the cost of ranibizumab is immense: monthly injections at a dose of 0.5 mg result in an annual cost greater than US \$23,000 per patient [@pone.0109744-Campbell1].

Similar to ranibizumab, bevacizumab (Avastin, Genentech, Inc., South San Francisco, CA, USA) is a recombinant humanized full-length antibody that can inhibit all isoforms of VEGF-A [@pone.0109744-Schmucker1]. In 2004, it was approved for the treatment of metastatic cancer of the colon or rectum, but it has not gained FDA approval for intravitreal use. Therefore, it can be utilized only in an off-label setting. For the past several years, it has been used off-label to treat wet AMD with very encouraging results. Bevacizumab has attracted more and more interest because of its low cost, which is especially important considering the number of injections that are necessary at 4- to 6-week intervals. A report suggested that the US medicare system could save more than US\$1 billion within 2 years if bevacizumab replaced ranibizumab [@pone.0109744-Frampton1], [@pone.0109744-Campbell1].

Although anti-VEGF agents are injected in small quantities into the eye, concerns about systemic safety have been raised, especially for the off-label use of bevacizumab. Research has shown that the systemic administration of bevacizumab, along with chemotherapeutic agents, can increase the risk of thromboembolic events two-fold over chemotherapy alone [@pone.0109744-Hurwitz1]. Many recently published randomized clinical trials (RCTs) have evaluated intravitreal bevacizumab and ranibizumab for the treatment of wet AMD. The results of the comparison of the AMD Treatments Trial (CATT) and the Age-related Choroidal Neovascularization Trial (IVAN) demonstrated that bevacizumab was not inferior to ranibizumab in the treatment of wet AMD [@pone.0109744-Chakravarthy1], [@pone.0109744-Martin1]. However, these studies were not sufficiently powerful to detect drug-specific differences in the rates of systemic adverse events. Hence, the crucial question of whether adverse effects differ between off-label bevacizumab and licensed ranibizumab has not yet been answered [@pone.0109744-Cheung1].

To determine whether the intravitreal injection of bevacizumab creates a higher risk of systemic adverse events than ranibizumab injection does, we undertook a systematic review and meta-analysis of all relevant head-to-head RCTs.

Methods {#s2}
=======

This study was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement ([Checklist S1](#pone.0109744.s001){ref-type="supplementary-material"}) [@pone.0109744-Moher1]. All stages of study selection, data extraction, and quality assessment were performed independently by two reviewers (W.W. and X.Z.). Any disagreement was resolved via discussion and consensus.

1. Literature Search {#s2a}
--------------------

Studies were identified through a systematic search of Pubmed, Embase, the Chinese Biomedicine Database, and the Cochrane library from inception up to December 2013. The initial search terms were (Ranibizumab or Lucentis) AND (Bevacizumab or Avastin) AND ("Macular degeneration" or AMD), which were filtered by "Humans" and "Randomized Controlled Trial." In addition, the reference lists of identified studies were manually checked to include other potentially eligible trials. This process was performed iteratively until no additional articles could be identified.

2. Study Selection {#s2b}
------------------

Studies were considered acceptable for inclusion in the meta-analysis if they met the following criteria: (1) the study design included randomized clinical trials; (2) the population was patients with wet AMD; (3) the interventions were intravitreal bevacizumab and intravitreal ranibizumab, which were directly compared in head-to-head design; (4) the incidence of systemic adverse events was reported; (5) there was a follow-up time of at least 1 year; and (6) there were at least ten patients in each arm. If there were multiple reports for a particular study, the most recent publication was included. Trials were excluded if they (1) were abstracts, letters, or meeting proceedings; (2) had repeated data or did not report outcomes of interest; or (3) included patients with other indications than wet AMD, patients previously treated with VEGF inhibitors, or patients receiving systemic anti-VEGF therapy.

3. Data Extraction {#s2c}
------------------

The following information was extracted from each study: first author; year of publication; study design; inclusion and exclusion criteria; number of patients in each group; characteristics of the study population; adverse events; the period, and number of injections preceding an adverse event. A Thromboembolic Event (TEE) was defined as any arteriothrombotic or venous thrombotic event [@pone.0109744-Abouammoh1].

4. Quality Assessment {#s2d}
---------------------

The methodological quality of each trial was evaluated using the Jadad scale [@pone.0109744-Jadad1]. The scale consists of three items describing randomization (0--2 points), blinding (0--2 points), and dropouts and withdrawals (0--1 points) in the reporting of a randomized controlled trial. A score of 1 is given for each of the points described. A further point is awarded when the method of randomization and/or blinding is given and is appropriate, whereas when it is inappropriate, a point is deducted. The quality scale ranges from 0 to 5 points. Higher scores indicate better reporting. The studies are said to be of low quality if the Jadad score is ≤2 and of high quality if the score is ≥3.

5. Statistical Analysis {#s2e}
-----------------------

All outcomes were expressed as risk ratios (RRs) with accompanying 95% confidence intervals (CIs). Outcome measure was assessed on an intent-to-treat (ITT) basis, the ITT population being comprised of all randomized patients who received the study medication and provided a valid baseline measurement. The cochrane Q test was used to detect the heterogeneity of the effects. Significant heterogeneity was defined as a P value of \<0.05. A fixed-effects model or random-effects model was used, depending on the presence or absence of heterogeneity. The I*^2^* value was used to demonstrate the percentage of the variability attributable to heterogeneity rather than to sampling error. Studies with an I*^2^* statistic of \<25% are considered to have no heterogeneity, those with an I*^2^* statistic of 25% to 50% are considered to have low heterogeneity, those with an I*^2^* statistic of 50% to 75% are considered to have moderate heterogeneity, and those with an I*^2^* statistic of \>75% are considered to have high heterogeneity [@pone.0109744-Higgins1]. Sensitivity analyses were performed by investigating the influence of a single study on the overall pooled estimate via omitting one study at a time. Potential publication bias was assessed by using Begg\'s and Egger\'s tests [@pone.0109744-Egger1], [@pone.0109744-Begg1]. A P value \<0.05 was judged to be statistically significant, except when otherwise specified. All statistical analyses were performed using Stata version 12.0 (Stata Corp, College Station, TX).

Results {#s3}
=======

1. Literature Search {#s3a}
--------------------

The selection process and reasons for exclusion are detailed in [Figure 1](#pone-0109744-g001){ref-type="fig"}. The initial search identified 125 potentially relevant articles, of which 71 were excluded based on the titles and abstracts. The remaining 54 were retrieved for a full-text review, and 40 of them were excluded because 38 included unqualified patients, two involved unqualified interventions, eight contained duplicated data [@pone.0109744-Ying1]--[@pone.0109744-Subramanian1], one did not report outcomes of interest [@pone.0109744-Biswas1], and one contained only one patients (\<10) in the ranibizumab arm [@pone.0109744-Subramanian2]. Thus, four RCTs [@pone.0109744-Chakravarthy1], [@pone.0109744-Martin1], [@pone.0109744-Krebs1], [@pone.0109744-Kodjikian1] were included in the final meta-analysis.

![Flowchart of studies included in meta-analysis. RCT, randomized controlled trial.](pone.0109744.g001){#pone-0109744-g001}

2. Study Characteristics and Quality {#s3b}
------------------------------------

The main characteristics of the four RCTs included in the meta-analysis are presented in [Table 1](#pone-0109744-t001){ref-type="table"}, and the outcome data of each included trial are described in [Table 2](#pone-0109744-t002){ref-type="table"}. These studies were published between 2012 and 2013. The sizes of the RCTs ranged from 317 to 1,185 patients (a total of 2,613; 1,291 with bevacizumab and 1,322 with ranibicizumab). Of the four trials, one was done in the USA [@pone.0109744-Martin1], one in the UK [@pone.0109744-Chakravarthy1], one in France [@pone.0109744-Kodjikian1], and one in Australia [@pone.0109744-Krebs1]. The trials included in this meta-analysis appeared to have been reasonably designed and conducted. All studies had a statement regarding randomization and double-blindness. Four trials described the methods of randomization. Four trials reported withdrawals and dropouts. All trials described the main outcome, and no missing data seemed to influence the results. The Jadad score of the studies included was 5.

10.1371/journal.pone.0109744.t001

###### Baseline characteristics of the head-to-head studies comparing ranibizumab with bevacizumab.

![](pone.0109744.t001){#pone-0109744-t001-1}

  Study    Location   Center   Blind    Duration       Intervention        No. of eyes   Age (years)   Male (%)   Visual acuity (letters)   Foveal thickness (mm)
  ------- ---------- -------- -------- ---------- ----------------------- ------------- ------------- ---------- ------------------------- -----------------------
  CATT       USA        44     double   2 years     Ranibizumab Monthly        301        79.2±7.4      39.2%            60.1±14.3                 458±184
                                                    Bevacizumab Monthly        286        80.1±7.3      37.1%            60.2±13.1                 463±196
                                                   Ranibizumab as Needed       298        78.4±7.8      37.9%            61.5±13.2                 458±193
                                                   Bevacizumab as Needed       300        79.3±7.6      38.7%            60.4±13.4                 461±175
  IVAN        UK        23     double   2 years         Ranibizumab            314        77.8±7.6       41%             67·8±17·0               471.6±192.5
                                                        Bevacizumab            296        77.7±7.3       39%             66·1±18·4               465.6±183.1
  GEFAL     France      38     double    1 year         Ranibizumab            129       78.68±7.27     31.21%          55.78±13.99             354.75±109.90
                                                        Bevacizumab            119       79.62±6.90     35.82%          54.62±14.07             359.21±120.72
  MANTA    Austria      10     double    1 year         Ranibizumab            163        77.6±8.1      36.20%           56.4±13.5                365.0±8.1
                                                        Bevacizumab            154        76.7±7.8      36.36%           57.0±13.0                374.6±8.4

CATT =  The Comparison of Age-related macular degeneration Treatments Trials; IVAN  =  The Alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularization study; MANTA  =  The Multicenter Anti-VEGF Trial; GEFAL  =  The Groupe d\'Etude Français Avastin versus Lucentis dans la DMLA néovasculaire (The French Study Group Avastin versus Lucentis for neovascular AMD).

10.1371/journal.pone.0109744.t002

###### Outcome data of randomized controlled trials included in the meta-analysis.
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  Adverse events                          CAAT    IVAN   GEFAL   MANTA                
  ------------------------------------- -------- ------ ------- ------- ---- ---- --- ---
  **Systemic adverse event**                                                          
  Death-all causes                         32      36     15      15     3    2    2   3
  Arteriothrombotic events               28^\*^    29     13      10     1    1    3   5
  Stroke                                   8       8       6       3     0    0    1   1
  Nonfatal myocardial infarction           9       7       4       4     1    1    2   3
  Vascular death                           12      14      3       4     0    0    0   0
  Venous thrombotic events                 3       10      3       4     0    1    0   0
  Hypertension                             3       4       0       0     2    1    0   0
  **MedDRA system organ class**                                                       
  Cardiac disorders                        47      62     20      19     5    2    1   1
  Infections                               41      54      9      12     2    4    3   3
  Nervous system disorders                 34      36      9       8     0    3    1   2
  Injury and procedural complications      23      35     12      10     2    4    3   2
  Neoplasms benign and malignant           27      22     11      14     1    1    2   1
  Surgical and medical procedures          0       0      16      14     0    5    0   1
  Gastrointestinal disorders               11      28      3       9     5    3    0   0
  Any other system organ class             81     104     25      27     11   10   2   3

3. Risk of Systemic Adverse Events {#s3c}
----------------------------------

The risk estimates for systemic adverse events associated with intravitreal bevacizumab, as compared with ranibizumab, were summarized in [Table 3](#pone-0109744-t003){ref-type="table"}. No significant differences between bevacizumab and ranizumab were found in terms of the incidence of death from all causes, arteriothrombotic events, stroke, nonfatal myocardial infarction, vascular death, venous thrombotic events, and hypertension, with the pooled RRs being 1.11 (0.77, 1.61), 1.03 (0.69,1.55), 0.84 (0.39,1.80), 0.97 (0.48, 1.96), 1.24 (0.63, 2.44), 2.38 (0.94, 6.04), and 1.02 (0.29, 3.62), respectively. When any arteriothrombotic or venous thrombotic events, such as TEE, were combined, no significant difference was detected (RR, 1.22; 95% CI: 0.85 to 1.75; P = 0.292) ([Figure 2](#pone-0109744-g002){ref-type="fig"}). Furthermore, when adverse events were divided by MedDRA system organ class, there was also no significant difference between bevacizumab and ranibizumab injections. The tests for heterogeneity were all non-significant (all P\>0.1). We tested the robustness of our analyses by performing sensitivity analyses excluding the CATT study (largest trial). Excluding this study did not change our final results.

![Risk ratio of thromboembolic events associated with intravitreal bevacizumab compared with ranibizumab.\
Each study is shown by the point estimate of relative risk "risk ratio" (RR) - the size of the square is proportional to the weight of the study - and 95%confidence interval for the RR (lines extending from the squares); the pooled RR and 95%confidence interval are shown as a diamond.](pone.0109744.g002){#pone-0109744-g002}

10.1371/journal.pone.0109744.t003

###### Risk ratio of systemic adverse events associated with intravitreal bevacizumab compared with ranibizumab.
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  Avastin vs Lucentis                    Study(n)   RR (95%CI)   Heterogeneity   Overall Effect                          
  ------------------------------------- ---------- ------------ --------------- ---------------- ------- -------- ------ -------
  Death-all causes                          4          1.11          0.77             1.61        0.907   0.00%    0.56   0.572
  Arteriothrombotic events                  4          1.03          0.69             1.55        0.828   0.00%    0.15   0.879
  Stroke                                    3          0.84          0.39             1.80        0.737   0.00%    0.46   0.649
  Nonfatal myocardial infarction            4          0.97          0.48             1.96        0.925   0.00%    0.09   0.928
  Vascular death                            2          1.24          0.63             2.44        0.842   0.00%    0.61   0.541
  Venous thrombotic events                  3          2.38          0.94             6.04        0.676   0.00%    1.83   0.067
  Hypertension                              2          1.02          0.29             3.62        0.471   0.00%    0.03   0.977
  MedDRA system organ class                                                                                              
  Cardiac disorders                         4          1.20          0.88             1.62        0.460   0.00%    1.16   0.245
  Infections                                4          1.36          0.97             1.91        0.965   0.00%    1.79   0.074
  Nervous system disorders                  4          1.11          0.75             1.66        0.606   0.00%    0.52   0.602
  Injury and procedural complications       4          1.31          0.87             1.98        0.578   0.00%    1.30   0.194
  Neoplasms benign and malignant            4          0.96          0.62             1.48        0.743   0.00%    0.18   0.854
  Surgical and medical procedures           3          1.75          0.43             7.16        0.222   33.60%   0.78   0.434
  Gastrointestinal disorders                3          1.90          0.78             4.62        0.141   49.00%   1.41   0.158
  Any other system organ class              4          1.25          0.99             1.56        0.803   0.00%    1.90   0.058

4. Publication Bias {#s3d}
-------------------

Due to the limited number (\<10) of studies included in each analysis, publication bias was not assessed.

Discussion {#s4}
==========

The development of VEGF inhibitors has revolutionized the treatment of AMD. Bevacizumab and ranibizumab are the two most common VEGF inhibitors in ophthalmic practice [@pone.0109744-Mitchell1]. Although anti-VEGF agents are injected into the eye in small quantities, concerns about systemic safety have been raised [@pone.0109744-Aujla1]. Until relatively recently, high-quality data comparing the efficacy and safety of ranibizumab and bevacizumab in AMD were lacking. Because many adverse events are relatively uncommon, clinical trials often lack the power to detect small but clinically important risk differences. Hence, meta-analyses pooling data from multiple studies provide important insights [@pone.0109744-Cheung1], [@pone.0109744-Torjesen1]. The main aim of this study is to provide an evidence-based analysis of the safety profile for bevacizumab versus that of intravitreal ranibizumab injections in patients with AMD. In the present meta-analysis, we have reviewed the literature regarding the safety of intravitreal bevacizumab as compared with that of ranibizumab. The pooled results suggest that the incidence of specific systemic complications did not differ significant between bevacizumab and ranibizumab. Also, no heterogeneity was observed across the studies.

Several high-quality non-randomized studies [@pone.0109744-Campbell2]--[@pone.0109744-Curtis1] focusing on adverse effects for bevacizumab versus ranibizumab are summarized in [Table 4](#pone-0109744-t004){ref-type="table"}. All of them reported that the rates of specific systemic adverse events, such as all-cause mortality, stroke, acute myocardial infarction, and venous thromboembolism during the bevacizumab and ranibizumab periods were not different. However, the limitation of these studies was that a non-randomized study design was used (case control or cohort study). The principal finding of our meta-analysis is consistent with the aforementioned studies on the topic.

10.1371/journal.pone.0109744.t004

###### Summary of high-quality non-randomized studies comparing ranibizumab with bevacizumab.
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  Author, country                                    Design                                                                          Population                                                                                                                                                                                                    Method                                                                                                                                                                                                                                                                                                                                 Results
  ------------------------------- -------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Campbell et al., 2012, Canada    Population based nested case-control study   Older adults with a history of physician diagnosed retinal disease identified between 1 April 2006 and 31 March 2011.   Cases were patients admitted to hospital for ischaemic stroke, acute myocardial infarction, venous thromboembolism, for congestive heart failure. Event-free controls were matched to cases on the basis of year of birth, sex, history of the outcome in the previous 5 years, and diabetes   Adjusted odds ratios for bevacizumab relative to ranibizumab were 1.03 (0.67 to 1.60) for ischaemic stroke, 1.23 (0.85 to 1.77) for acute myocardial infarction, 0.92 (0.51 to 1.69) for venous thromboembolism, and 1.35 (0.93 to 1.95) for congestive heart failure. Results showed these risks did not differ significantly between bevacizumab and ranibizumab injections.
  Campbell et al., 2012, Canada      Population-based, time series analysis       All patients aged 66 years or older with physician-diagnosed retinal disease between 2002 and 2010 (N = 116 388).                                                            Segmented regression analysis was used to evaluate changes in the rate of hospitalization for ischemic stroke associated with the introduction of bevacizumab and ranibizumab.                                                                                           Bevacizumab trend change coefficient: -0.0026 stroke hospitalizations/1000 subjects/month (P = 0.20); Ranibizumab trend change coefficient: -0.0011 stroke hospitalizations/1000 subjects/month (P = 0.78). Results showed that stroke rates in the bevacizumab and ranibizumab periods were not different.
  French et al., 2011, USA                        Cohort study                  Beneficiaries of the Veterans Health Administration aged ≥55 years with AMD in fiscal years 2007-2009 were included.                                         Anti-vascular endothelial growth factor exposure was identified through pharmacy records. Cox proportional hazard model was adjusted for age, gender, number of injections, and ocular and medical comorbidities.                                                                                                         The adjusted HR for all-cause mortality were 0.94 (95%CI: 0.72 to 1.22) for bevacizumab and 0.85 (95%CI: 0.67 to1.08) for ranibizumab. Results showed lack an association between the use of either ranibizumab or bevacizumab and mortality.
  Curtis et al., 2010, USA                        Cohort study                         Medicare beneficiaries 65 years or older with a claim for AMD in fiscal years 2005-2006 were included.                        When the patients received a therapy different from the initial therapy, the data were censored. The associations between anti-VEGF therapies and the risks of all-cause mortality, incident myocardial infarction, bleeding, and incident stroke were calculated.                                             Adjusted HRs for ranibizumab relative to bevacizumab were 0.90 (0.79-1.02) for all-cause mortality, 0.84 (0.66-1.06) for myocardial infarction, 1.03 (0.93-1.15) for bleeding, 0.81 (0.68-0.98) for stroke. Results showed these risks did not differ significantly between bevacizumab and ranibizumab injections.

Thus far, ranibizumab and bevacizumab have been evaluated in several systematic reviews [@pone.0109744-Schmucker1], [@pone.0109744-Abouammoh1], [@pone.0109744-Mitchell1], [@pone.0109744-Schmucker2]. However, the published reviews focused on the beneficial effects and clinical effectiveness of VEGF inhibitors, without adequately addressing their adverse effects. Furthermore, they are mainly based on indirect comparative studies; this may lower the evidence level. In Schmucker and colleagues\' report [@pone.0109744-Schmucker2], only one multiple-center, head-to-head RCT (CATT) was included; it had relatively modest sample sizes. In another meta-analysis by Chakravarthy et al. [@pone.0109744-Chakravarthy1], no difference in the frequency of death, arterial thrombotic events, or hospital admission for heart failure was recorded between the drugs. Their study is limited by the fact that only 1-year CATT data were included. In our study, we incorporated the 2-year CATT data and two other well-designed RCTs. We found a similar risk of specific adverse events between the bevacizumab and ranibizumab groups. From a theoretical viewpoint, the risk of the development of systemic adverse events may be higher with bevacizumab than with ranibizumab [@pone.0109744-Campbell1]. Bevacizumab is more likely to induce immunologic activation and will remain in systemic circulation than ranibizumab. Thus, bevacizumab administration may create a higher risk of systemic adverse events. These highlight the need for ongoing surveillance and large population-based studies to investigate these outcomes [@pone.0109744-Cheung1].

The results of this meta-analysis must be interpreted cautiously in light of the strengths and limitations of the included trials. A key strength of this study is the fact that all the studies included in this meta-analysis were published by established centers of excellence using a randomized controlled design and all of them were well-performed and of high quality. In addition, with the enlarged sample size, we have enhanced statistical power to provide more precise and reliable effect estimates. Despite our rigorous methodology, some limitations of the current study should not be ignored. First, we cannot fully exclude publication bias. The number of included studies is insufficient to carry out further statistical testing to detect publication bias through an asymmetry plot. In addition, we did not attempt to gain access to unpublished results. More RCTs are warranted to confirm or refute our finding in the future update meta-analysis. Second, all studies have come from western populations with predominately Caucasian participants. The relatively good distribution of the study population makes findings from this meta-analysis a fair representation of the general population. The safety of these drugs for other ethnicities, such as Asians, must be tested. Furthermore, patients enrolled in RCTs meet strict eligibility criteria, which may exclude many patients at a higher risk for systemic adverse events. These limitations likely resulted in an underestimation of the incidence of systemic adverse events. However, the determination of the risk of systemic adverse events associated with bevacizumab versus ranibizumab was not likely affected, because this underestimation should have had similar impacts on both arms. Finally, given that the treatment of wet AMD is not limited to 2 years, more data from studies of longer durations are needed to determine the relative safety of each anti-VEGF agent over the long term.

In conclusion, there is no difference between bevacizumab and ranibizumab in terms of the risk of specific systemic adverse events. However, the results should be interpreted cautiously because the relevant evidence remains limited, and the findings must be confirmed through future research involving well-designed cohort studies or RCTs.
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